Theragnostics Announces that its Radiotherapeutic for Treatment of Glioblastoma Multiforme has been Awarded UK's MHRA Innovation Passport

Corporate Breaking News

Home : Theragnostics Announces that its Radiotherapeutic for Treatment of Glioblastoma Multiforme has been Awarded UK's MHRA Innovation Passport

Feb 10 2022	Theragnostics Announces that its Radiotherapeutic for Treatment of Glioblastoma Multiforme has been Awarded UK's MHRA Innovation Passport
LONDON, Feb. 10, 2022 /PRNewswire/ -- Theragnostics, which is developing radiopharmaceuticals for imaging and treatment of cancer, today announces that its novel I-123 PARPi (THG-009) therapeutic agent has been awarded an Innovation Passport by the UK Medicines and Healthcare products...


Source:https://www.prnewswire.com:443/news-releases/theragnostics-announces-that-its-radiotherapeutic-for-treatment-of-glioblastoma-multiforme-has-been-awarded-uks-mhra-innovation-passport-301479002.html

Related News
» Lynx Air, Canada's new ultra-affordable airline, uses IBS Software's iFlight to power its operations » Sportereignisse aus aller Welt für Zuschauer in Asien: Eclat Media Group arbeitet mit Tata Communications zusammen